Knowthestock.com
ABMD - Abiomed Inc.
SNP 500

Sell

Strong Growth but DecliningStock Price High

77%

based on last 5 year data.
Income Statement is STRONG
Revenue Growth is -3.37%
Operating Income Growth is -12.38%
Net Income Growth is -18.23%
Earnings Per Share (EPS) Growth is -17.48%
Net Margin is 24.66%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 5.76
Debt Ratio is 0.12
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is STRONG
Cash from Operations Growth is -8.04%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is Moderate
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Abiomed Inc. (ABMD) - http://www.abiomed.com/
Abiomed is a publicly-traded medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump. The company is headquartered in Danvers, Massachusetts and has three additional offices, two in Germany in the cities of Berlin and Aachen, and another in Tokyo, Japan. Michael R. Minogue is Chairman, CEO & President of the company, with Dr. Thorsten Siess as Chief Technology Officer, Dr. Chuck Simonton as Chief Medical Officer and Dr. David M. Weber as Chief Operating Officer. According to Bloomberg, the company "engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients". As of 2019, the company had secured five FDA approvals and 715 patents with 622 pending. For fiscal year 2019, Abiomed reported $769.4 million in revenue and reported diluted earnings per share was $5.61 for the year. Abiomed was founded in Danvers, Massachusetts by David M. Lederman in 1981 as Applied Biomedical Corporation. That year, the company commenced the development of an artificial heart. Funded by federal research grants, Lederman partnered with The Texas Heart Institute to develop the AbioCor, a grapefruit-sized electromagnetic device with an internal battery that completely replaces the heart without wires or tubes passing through the skin. In July 2001, AbioCor became the first artificial heart successfully implanted in a patient, where it pumped more than 20 million times. Fourteen of the AbioCor devices were implanted, during clinical trials from 2001 to 2004, with the longest-living recipient surviving 512 days. The AbioCor won FDA approval in 2006 for patients who are near death and do not qualify for a heart transplant.
Exchange - NASDAQ/NGS (GLOBAL SELECT MARKET)
Industry - Surgical and Medical Instrument Manufacturing
Sector - Manufacturing
CEO - Michael Minogue
Employees - 1,371
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.